Search results
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
This edition of Look Forward is packed full of details of our plans for 2022. There is so much going on and being able to get together in person is a big part of that.
The following questions are often asked by people contacting Retina UK.
A recording of the 46th Retina UK Annual Conference on 24 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.
The Great North Run is the largest half marathon in the world, taking place annually in Newcastle.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Growth factors are substances that promote the health and function of cells and tissues in the body.
ProQR has published the top-line results from its Phase 2/3 “Illuminate” trial of the RNA therapy sepofarsen for Leber congenital amaurosis type 10 caused by a specific mutation in the CEP290 gene.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
